Bladder cancer specific ligand peptides
AssigneeThe Regents of the University of California
InventorsChong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
Life of this patent
Estimating the term…
Abstract
The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
Claims37
A method of inhibiting the growth or proliferation of or killing a bladder cancer cell in a subject in need thereof, comprising contacting bladder tissue with a peptide, linked to a therapeutic moiety;
- wherein the peptide comprises the amino acid sequence X1DGRX5GF (SEQ ID NO:2), wherein X1 is selected from Gln and Gly and X5 is any amino acid other than cysteine, wherein the peptide is no longer than 25 amino acids in length, and binds to bladder cancer cells, and is recombinant and/or synthetic;
- wherein the peptide binds to bladder cancer cells and the therapeutic moiety inhibits the growth of or kills the bladder cancer cells.
A method of inhibiting the growth or proliferation of a bladder cancer cell in a subject in need thereof, comprising contacting bladder tissue with a peptide, linked to a therapeutic moiety;
- wherein the peptide comprises the amino acid sequence X1DGRX5GF (SEQ ID NO:2), wherein X1 is selected from Gln, Gly and Ala and X5 is any amino acid other than cysteine, and the peptide comprise one or more of:
- i) one or more of the amino acid residues are D-amino acids;
- ii) protecting groups at one or both of the N-terminus and the C-terminus;
- iii) two or more repeats of the amino acid sequence X1DGRX5GF (SEQ ID NO:
- 2), wherein X1 is selected from Gln, Gly and Ala and X5 is any amino acid other than cysteine;
- and
- iv) one or both of an N-terminal D-cysteine and a C-terminal D-cysteine and is circularized,
- wherein the peptide does not comprise a combination of ii) and iv), is no longer than 25 amino acids in length, binds to bladder cancer cells, and is recombinant and/or synthetic;
- and
- wherein the peptide binds to bladder cancer cells and the therapeutic moiety inhibits the growth of the bladder cancer cells.
A method of inhibiting the growth of a bladder cancer cell in a subject in need thereof, comprising contacting bladder tissue with a peptide comprising the amino acid sequence X1DGRX5GF, wherein X1 is selected from Gln and Gly and X5 is any amino acid other than cysteine, wherein the peptide is no longer than 10 amino acids in length and is recombinant and/or synthetic, wherein the peptide is linked to a therapeutic moiety, wherein the peptide binds to bladder cancer cells and the therapeutic moiety inhibits the growth of the bladder cancer cells.
Dependencies are inferred from the claim text.